



Mili Arora, M.D.

Clinical Interests	Dr. Arora's clinical interests are in breast cancer, benign and malignant hematology.
Title	Assistant Professor (HSCP)
Specialty	Hematology/Oncology, Cancer , Benign and Malignant Hematology, Oncology, Breast Cancer
Department	Internal Medicine
Division	Hematology and Oncology
Center/Program Affiliation	UC Davis Comprehensive Cancer Center
Address/Phone	UC Davis Comprehensive Cancer Center, Hematology/Oncology Clinic, 4501 X Street 2nd Floor Sacramento, CA 95817 Phone: 916-734-5959
Additional Phone	Clinic Fax: 916-703-5265 Clinic Referral Phone: 916-703-5210 Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Education	M.D., George Washington University, Washington DC 2009 B.S., Virginia Commonwealth University, Richmond VA 2004
Residency	Internal Medicine, Tufts Medical Center, Boston MA 2009-2012
Fellowships	Hematology/Oncology, UC Davis Medical Center, Sacramento CA 2012-2015
Board Certifications	American Board of Internal Medicine
Professional Memberships	American College of Physicians (ACP) American Society of Clinical Oncology American Society of Hematology (ASH) Southwest Oncology Group (SWOG)
Honors and Awards	Placer Breast Cancer Foundation award for research/trial work, 2019 Christine and Helen Landgraf Memorial Research Award recipient, 2019 Chief Fellow, UC Davis, 2014, 2015
Select Recent Publications	For a comprehensive list of Dr. Arora's publications, please click here (opens new window).



Mili Arora, M.D.

Sauder C, Li Q, Othieno A, Cruz D, Arora M, Bold R, Meyers F, Keegan T. Characteristics and outcomes for secondary breast cancer in children, adolescent and young adult cancer survivors treated with radiation. *Cancer Epidemiology Biomarkers & Prevention*. 2020 Sept. doi: 10.1158/1055-9965.EPI-20-0260.

Poh C, Arora M, Ghuman S, Tuscano J. Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia. *Acta Haematologica*. 2020 Apr;1-5. doi:10.1159/000506918. PMID: 32348994.

Tomlinson BK, Tuscano JM, Abedi M, Welborn J, Arora M, O'Donnell RT, Wun T, Jonas BA. A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. *Am J Hematol*. 2019 Nov;94(11):e291-294. doi:10.1002/ajh.25605. Epub 2019 Aug 20. PMID:31379016.

Bateni SB, Davidson AJ, Arora M, Daly ME, Stewart SL, Bold RJ, Canter RJ, Sauder CAM. Is Breast-Conserving Therapy Appropriate for Male Breast Cancer Patients? A National Cancer Database Analysis. *Ann Surg Oncol*. 2019 Jul;26(7):2144-2153. doi:10.1245/s10434-019-07159-4. Epub 2019 Feb 13. PMID:30761438. PMCID:PMC6545266.

Schwab E, Chen JA, Huynh JC, Ji J, Arora M, Cho M, Kim EJ. Rational Strategies for Combining Bcl-2 Inhibition with Targeted Drugs for Anti-Tumor Synergy. *J Cancer Treatment Diagn*. 2019;3(4):7-13.

Arora M, Gowda S, Tuscano J. A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma. *Ther Adv Hematol*. 2016 Aug;7(4):209–221. Published online 2016 Jul 1. doi:10.1177/2040620716652861. PMID:27493711.

Chew H, Arora M, Verman R. Breast Cancer. Ed. Robert M. McCarron, Glen L. Xiong, and Henry



Mili Arora, M.D.

A. Nasarallah, (ed). Preventive Medical Care in Psychiatry, First ed. 2014;19:275-288.

Arora M, Wun T. Adverse impact of venous thromboembolism on patients with cancer. *Semin Thromb Hemost.* 2014 Apr;40(3):313-8. doi:10.1055/s-0034-1370769. Epub 2014 Mar 5. PMID: 24599435.

Arora M, Cossor F. Diagnosis of extracavitary primary effusion lymphoma by urine cytology. *Blood.* 2012;119(12):2707. doi:10.1182/blood-2011-04-319103.

Kimchi-Sarfaty C, Arora M, Marple CH, Kimchi A, Gurwitz D, Gottessman M. Ethnicity-Related Polymorphisms and Haplotypes in the Human ABCB1 gene. *Pharmacogenomics.* 2007 Jan;8(1):29-29. doi:10.2217/14622416.8.1.29. PMID:17187507.

© 2021 UC Regents